Truist Financial Maintains Buy Rating and $115 Price Target for Disc Medicine

Truist Financial analyst Danielle Brill has reaffirmed a 'Buy' rating and a price target of $115 for Disc Medicine, Inc. (NASDAQ: IRON). This decision reflects the firm's positive outlook on the biopharmaceutical company amid recent corporate developments, indicating confidence in its valuation and growth potential.